models with log-rank tests to determine survival in Kaplan-Meier curves. P < .05 was the threshold for significance.
Objectives: Vascular surgery (VS) is projected to be one of the specialties with the highest growth needs to meet future demand in the United States. Over the past decade, the VS community has initiated multiple efforts to increase the supply of vascular surgeons. This study seeks to determine the effects of these efforts on current and future work force.
Methods: The available practicing physician data (from the American Board of Medical Specialties and American Medical Association) and graduate medical education information (National Resident Matching Program) were obtained from 2007 to 2017. The Healthcare Cost and Utilization Project Nationwide Inpatient Sample was queried for all vascular procedures performed on adult patients (age > 18) and population data were obtained from the U.S. Census Bureau.
Results: Between 2007 and 2014, there was an annual increase of 2.6% per year (907,198 to 1,071,105) in inpatient adult vascular procedures and an increase of 1.3% per year (237 to 245 million) in the adult population. During this time, there was a 43% increase (116 to 166) in available first year VS training positions per year with a 22% increase (133 to 162) in applicants annually. The match process resulted in a 35% increase (110 to 149) in trainees matched into first-year VS positions and a 21% increase (112 to 135) in new VS board certificates issued. The workforce data for VS compared with other specialties that participate in vascular care can be found in the Fig. Based on the assumption that trends in procedure volume increase remains constant and using population estimates, there is a need for an estimated 1833 additional vascular surgeons by 2030.
Conclusions: Despite the successful efforts leading to an increase in current supply of vascular surgeons, there remains a predicted deficit of vascular surgeons in the future. Increasing need and our aging workforce suggest a need to improve efforts for training and certifying vascular Abstracts (2012) (2013) (2014) were queried to construct a database of providers performing EVT for treatment of lower extremity venous reflux. For all providers performing EVT on more than 10 patients annually, practice patterns were assessed by calculating a use index: the number of EVT procedures per patient per year. To measure geographic variation in EVT use at the provider level, the median number of EVT performed annually per provider per year was calculated. Multivariate regression analysis was used to identify provider characteristics (including specialty, site of service, and geography) associated with high intensity use of EVT (a use index >75th percentile).
Journal of Vascular Surgery
Results: There were 6599 providers who performed more than 10 EVT per year in Medicare beneficiaries, accounting for 405,232 services. The intensity of EVT use by providers was assessed by the calculated use index: the average number of EVT performed per patient per year (range, 1-4). Vascular surgeons had the lowest use index among all provider specialties (1.32; Fig 2) . By multivariate analysis, the likelihood of a providers use index being greater than 1.8 (top 25%) was associated with provider training in a field other than surgery, cardiology, or radiology (odds ratio, 3.35; 95% confidence interval, 2.74-4.09), services performed in an outpatient setting (odds ratio, 2.62; 95% confidence interval, 1.97-3.47), and providers who perform high annual volume of EVT (odds ratio, 8.68; 95% confidence interval, 7.59-9.91). A high annual volume provider was defined as one whose EVT volume was at or greater than the 75th percentile nationally.
Conclusions: There is great variation in intensity of vein ablation procedures performed on Medicare beneficiaries that cannot readily be explained by clinical factors alone. The likelihood that a provider will perform multiple EVT on a patient within a given calendar year is predictable based on the provider's geographic location, site of service (facility vs hospital), specialty, and annual EVT volume. Of particular concern is the high intensity of EVT use by providers with specialty certification not typically associated with the management of venous disease.
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Safety and Performance of the Veniti VICI Venous Stent in Patients With Venous Outflow Obstructions: Results From the Arnsberg Venous Registry
Michael K. W. Lichtenberg. Arnsberg Clinic, Arnsberg, Germany
Objectives: To determine patency of the Veniti VICI venous stent device for the treatment of venous obstruction of the lower extremities.
Methods: From 2014 to 2016, patients undergoing a Veniti VICI venous stent implantation for venous outflow obstruction were analyzed for patency and clinical symptom resolution. Patient charts from this prospectively maintained registry were reviewed for patient demographics, patency and reinterventions, clinical, etiology, anatomy, and pathophysiology, and the revised Venous Clinical Severity score.
Results: A total of 90 consecutive patients (57% female; mean age, 57.4 years) were treated successfully during the aforementioned timeframe. The 12-month patency was 92.2%, 92.2%, and 93.9% for primary, assisted primary, and secondary patency, respectively. Five patients presented with stent reocclusion during the 12-month follow-up period and three of them underwent reintervention. Clinical improvement with a gain of two or more revised Venous Clinical Severity score levels was observed in 82%, 90%, and 76% of patients at 1, 6, and 12 months, respectively. Primary patency differed significantly between nonthrombotic iliac vein lesion and postthrombotic lesions. All nonthrombotic iliac vein lesions remained patent throughout 12 months, whereas postthrombotic lesions were associated with a 12-month primary patency rate of 85.7%.
Conclusions: The Veniti VICI venous stent holds promise as a treatment modality for chronic venous occlusion with good short-term patency and quality-of-life outcome. Long-term studies are needed to evaluate the durability of the procedure. 
